Healthcare News: CMS changes status indicators for 10 codes
CMS reassigned 10 codes to status indicator K (paid under OPPS; separate APC payment) as part of the July update to the Integrated Outpatient Code Editor.
The following two codes will have a status indicator K effective July 1:
- J1680, injection, human fibrinogen concentrate, 100 mg
- J9001, injection, doxorubicin hydrochloride, all lipid formulations, 10 mg
CMS reassigned the following eight codes to status indicator K effective April 1:
- 90581, anthrax vaccine, for subcutaneous or intramuscular use
- J2265, injection, minocycline hydrochloride, 1 mg
- J8650, nabilone, oral, 1 mg
- Q0174, thiethylperazine maleate, 10 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q4123, AlloSkin™ RT, per square centimeter
- Q4125, ArthroFlex™, per square centimeter
- Q4128, FlexHD® or AlloPatch HD™, per square centimeter
- Q4129, Unite® Biomatrix, per square centimeter
All 10 codes previously fell under status indicator E (not paid by Medicare when submitted on outpatient claims [any outpatient bill type]).